secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-11-20T23:59:59+00:00
Accession:  0000950170-23-065178
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics appoints Katie Ellias to Board of Directors, effective Nov 20, 2023
--------------------------------------------------------------------------------

- Appointed Katie Ellias as Class II director, effective Nov 20, 2023, until 2026 annual meeting.
- Ellias is Managing Director at JDRF T1D Fund (~$200M assets), which invested in SAB.
- Board now has 10 directors, 8 independent.
- Ellias brings T1D expertise; formerly at Endeavour Vision, Sofinnova Partners, Medtronic, McKinsey.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023065178/0000950170-23-065178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023065178/sabs-20231114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-065178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer